Latest Remuneration And Governance News

Supply Network Limited reported a 15.4% rise in FY2026 revenue to $403.7 million and a 19% jump in net profit to $47.6 million, underpinning a 44-cent fully franked final dividend. The company is advancing major branch expansions and IT upgrades to support its $50 million revenue growth target for FY2027.

WT Financial Group (ASX: WTL) delivered its sixth consecutive year of growth in FY2026, with net profit before tax up 19% to $6.55 million and a fully franked final dividend declared at 0.75 cents per share. The company also completed a strategic disposal of its B2C subsidiaries, advancing its Hubco investment model.

General Capital’s 2026 Annual Shareholders Meeting saw a notable board shake-up as investors declined to re-elect Brent Douglas King, while approving a near 10% hike in directors' remuneration.

Eureka Group Holdings (ASX: EGH) posted a 29% rise in underlying EBITDA for FY26, driven by rapid growth in its all-age rental segment and disciplined capital deployment, while statutory profit dipped due to one-off costs and tax adjustments.

Megaport has posted a 37% jump in FY26 revenue to $312 million, driven by strategic acquisitions and a broadening platform across compute, network, and storage. The company raised over $1 billion to fund AI-focused contracts and infrastructure growth.

Bega Cheese Limited has delivered a robust FY2026 with a $54.8 million statutory profit, a 6.7% revenue increase, and a raised final dividend of 7.5 cents per share. The company is advancing its strategic growth plans focused on high-protein products, international expansion, and sustainability initiatives.

EBOS Group posted a solid FY26, growing revenue nearly 10% to $13.5 billion and underlying EBITDA 5% to $614 million, while completing a major distribution centre renewal program. The company maintains its final dividend and sets a confident growth outlook for FY27.

GWA Group posted modest revenue and earnings growth in FY26, driven by volume gains across Australia, New Zealand, and the UK, while raising dividends and advancing strategic priorities despite challenging market conditions.

Orora’s FY26 results reveal a $616.6 million statutory loss driven by a $742.8 million Glass impairment, offset by robust growth in its Cans business and disciplined capital management.

Axel REE has appointed Dr Patience Mpofu as Managing Director, positioning the company to advance its rare earths portfolio from exploration into commercial development with planned in-situ recovery trials.

Ryman Healthcare nearly doubles operating profitability and generates positive free cash flow for the first time in over a decade, while shifting strategy toward sustainable growth and targeting dividend returns by FY28.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.